ZyVersa Therapeutics, Inc. - Warrants ZVSAW 深 沪
已收盘 12-20 16:00:00 美东时间
0.07
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.07
- 总市值 0
- 52周最高 0.30
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.037
- 委 比 0.00%
- 总股本 --
- 历史最高 0.30
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.037
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ZyVersa Therapeutics Stock Approved for OTCQB Listing
The latest update is out from ZyVersa Therapeutics ( ($ZVSA) ). On July 25, 202...
07-28 20:19
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
ZyVersa Therapeutics' CEO, Stephen C. Glover, updates shareholders on mid-year developments, highlighting $12 million in financing and progress in kidney and inflammatory disease treatments. Their VAR 200 drug targets kidney diseases, with Phase 2a trials in diabetic kidney disease expected to report preliminary data by Q4-2025. IC 100, an inflammasome inhibitor, is advancing for obesity and neurodegenerative diseases, with preclinical studies se...
07-21 11:55
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move
An announcement from ZyVersa Therapeutics ( ($ZVSA) ) is now available. On July...
07-17 00:58
ZyVersa Therapeutics Enters Warrant Exercise Agreement
The latest announcement is out from ZyVersa Therapeutics ( ($ZVSA) ). On July 8...
07-10 04:53
ZyVersa Therapeutics Provides Regulatory And Product Support For FDA-Authorized Emergency Compassionate Use Of Cholesterol Efflux Mediator VAR 200 In ApoCII Amyloidosis Patient
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine
07-08 19:54
ZyVersa Therapeutics Secures $10M Equity Purchase Agreement
ZyVersa Therapeutics ( ($ZVSA) ) has provided an announcement. On June 24, 2025...
06-25 21:31
ZyVersa Therapeutics Enters Into SPA For Up To $10M In Partnership With Williamsburg Venture Holdings To Fund Clinical Development Of Cholesterol Efflux Mediator VAR 200
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet
06-25 19:57
ZyVersa Therapeutics Highlights Newly Published Data Further Substantiating Potential Of Inflammasome ASC Inhibitor IC 100 As Disease-Modifying Treatment For PD
Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein leading to
05-20 20:54
ZyVersa Therapeutics Q1 EPS $(0.73) Misses $(0.40) Estimate
ZyVersa Therapeutics (NASDAQ:ZVSA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.40) by 82.5 percent. This is a 83.89 percent increase over losses of $(4.53) per share
05-13 04:38
ZyVersa Announces Release Of Inflammasome Inhibitors In Combination with GLP-1 Agonists To Address Unmet Medical Needs Of People Living with Obesity
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for Inflammasome ASC
05-07 19:59
